Neusspray Xylometazoline Hcl Htp (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Neusspray Xylometazoline Hcl Htp, is an imidazoline derivative presented as a nasal spray for nasal use. It relieves nasal congestion in adults and children experiencing colds, sinusitis, or allergic rhinitis.

GNH USA supplies Neusspray Xylometazoline Hcl Htp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is a nasal decongestant that reduces swelling of the nasal mucosa.

- Nasal congestion: provides temporary relief of blocked nose caused by common cold, sinusitis, or allergic rhinitis. - Allergic rhinitis: alleviates nasal blockage associated with seasonal or perennial allergies. - Acute sinusitis: helps reduce nasal obstruction during the early phase of sinus infection.

Xylometazoline Hydrochloride may cause local and systemic reactions.

Common Side Effects: - Nasal burning or stinging sensation. - Dryness of the nasal mucosa. - Sneezing shortly after application. - Mild headache. - Altered taste perception.

Serious or Rare Side Effects: - Rebound nasal congestion (rhinitis medicamentosa) with prolonged use. - Significant increase in blood pressure or hypertension. - Cardiac arrhythmias in susceptible individuals.

Use of Xylometazoline Hydrochloride should follow safety guidelines to minimize risks.

- Use duration: limit administration to 3‑5 consecutive days to avoid rebound congestion. - Age restrictions: not recommended for children under 2 years unless directed by a healthcare professional. - Pregnancy: consult a physician; safety data are insufficient. - Cardiovascular disease: use with caution in patients with hypertension or heart conditions. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Xylometazoline Hydrochloride can interact with other sympathomimetic agents.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase hypertensive risk. - Sympathomimetic decongestants (e.g., pseudoephedrine): additive vasoconstriction. - Tricyclic antidepressants: potential for elevated blood pressure.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may mask tachycardia caused by vasoconstriction. - Intranasal cocaine use: heightened risk of nasal ischemia.